Treatment compliance in early-stage anal cancer
- PMID: 32707167
- DOI: 10.1016/j.annonc.2020.07.006
Treatment compliance in early-stage anal cancer
Conflict of interest statement
Disclosure AD – travel grants: Amgen, Ipsen. AH – consultancy, advisory board: Amgen, Bayer, Eli Lilly, Merck, Pierre Fabre, Servier, Sirtex. Research funding: Amgen, AstraZeneca, Ipsen, Leo Pharma, Merck, Roche, Sanofi, Teva Pharma. Travel grant: Merck, Roche, Sirtex. FS – consultancy, advisory board: Bayer. Research funding: AstraZeneca, Bayer, BMS, Roche. Travel grants: Bayer, Lilly. All other authors have declared no conflicts of interest.
Comment on
-
Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III ACT II trial.Ann Oncol. 2020 Oct;31(10):1376-1385. doi: 10.1016/j.annonc.2020.06.012. Epub 2020 Jun 30. Ann Oncol. 2020. PMID: 32619648 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical